Insmed (INSM) Cost of Revenue (2018 - 2026)

Insmed's Cost of Revenue history runs 9 years deep, the most recent figure standing at $47.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 122.86% year-over-year to $47.4 million; the TTM figure through Mar 2026 stood at $149.1 million (up 66.45% YoY), while the FY2025 annual figure was $122.9 million, up 43.38% from the prior year.
• Cost of Revenue was $47.4 million for Q1 2026 at Insmed, up from $44.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $47.4 million in Q1 2026 to a low of $12.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $22.2 million across 5 years, with a median of $18.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cost of Revenue fell 1.65% in 2022, then jumped 122.86% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $13.1 million in 2022, then jumped by 41.12% to $18.4 million in 2023, then jumped by 41.79% to $26.2 million in 2024, then surged by 69.09% to $44.2 million in 2025, then increased by 7.24% to $47.4 million in 2026.
• The last three Cost of Revenue figures came in at $47.4 million (Q1 2026), $44.2 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.